Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (NASDAQ: VTRS) announced further details of its global restructuring initiative aimed at reducing costs by at least $1 billion by the end of 2024. The restructuring will impact up to 20% of its 45,000 global workforce and involve the closure or downsizing of 15 manufacturing facilities. The initiative is expected to incur pre-tax charges of $500 million to $600 million, with potential annual savings of $250 million to $300 million. The company remains committed to supply continuity and employee treatment during this transition.
Viatris (NASDAQ: VTRS) will present at the J.P. Morgan 39th Annual Healthcare Conference on January 14, 2021, at 7:30 a.m. ET, led by CEO Michael Goettler. Investors can listen live via the company's investor relations website. Additionally, Viatris will hold its inaugural Investor Day virtually on March 1, 2021, where leadership will discuss strategic plans and fiscal guidance for 2021. Webcasts for both events will be available live and archived at investor.viatris.com.
Sesame Workshop and Viatris have launched new resources aimed at supporting families' social and emotional needs during the COVID-19 pandemic. Available in multiple languages, these materials help children articulate feelings and encourage positive caregiving practices. The resources will be rolled out in various regions, including the U.S., India, and South Africa, as part of Sesame Workshop's Caring for Each Other initiative. Viatris, dedicated to public health, will share these resources with its workforce of 45,000 globally.
Viatris Inc. (NASDAQ: VTRS) received tentative FDA approval for pediatric dolutegravir tablets (10 mg) aimed at treating HIV in children, in collaboration with ViiV Healthcare and others. This approval is part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), allowing distribution in countries with urgent needs. Pediatric dolutegravir is also recommended by the World Health Organization as a first-line treatment for eligible children. Viatris provides treatments to approximately 60% of HIV-positive children globally, emphasizing its commitment to affordable healthcare solutions.